国产91视频久久,亚洲综合色图在线观看,五月天操逼网,日韩色色AV,青青在线A片,亚洲最大色在线观看,欧美熟妇丝袜诱惑,青青操逼视频,日韩无码操出水

 
Guideview > Gilead
  • Global Biopharma Layoffs January 2026
    Global Biopharma Layoffs January 2026 Layoffs This article tracks recent biotech and pharma layoffs, including major workforce cuts at Voyager Therapeutics, Intercept Pharmaceuticals, Mythic Therapeutics, Pfizer, and others, as companies restructure operations, streamline pipelines, and refocus resources amid shifting market conditions.
  • Gilead Q2 2025 Financial Report
    Gilead Q2 2025 Financial Report Financial statements Gilead's Q2 2025 results show strong HIV growth with Yeztugo approval but continued struggles in CAR-T therapies. Full-year guidance raised amid reliance on HIV business and strategic challenges ahead.
  • Sanofi and Gilead Expand Protein Degrader Portfolios
    Sanofi and Gilead Expand Protein Degrader Portfolios Sanofi Sanofi and Gilead deepen their partnerships with Kymera Therapeutics, focusing on next-gen protein degraders for cancer and immune diseases in multi-million dollar deals, signaling rising industry interest.
  • Global Biopharma Layoffs June 2025
    Global Biopharma Layoffs June 2025 Layoffs Biopharma layoffs surge in June 2025 as major companies like Genentech, Vertex, and Recursion downsize. Explore the latest job cuts, site closures, and restructuring trends across the industry.
  • FDA Puts Gilead’s HIV Combo Trials on Hold
    FDA Puts Gilead’s HIV Combo Trials on Hold Gilead The FDA has paused five Gilead HIV combo trials over safety concerns, but the decision does not impact lenacapavir's upcoming PrEP approval. Gilead remains confident in its HIV pipeline and future plans.
  • Trodelvy Shows Strong Solo Efficacy in TNBC
    Trodelvy Shows Strong Solo Efficacy in TNBC Gilead Gilead’s Trodelvy shows significant solo efficacy in the ASCENT-03 trial, outperforming chemotherapy in previously untreated TNBC patients not eligible for immunotherapy.
  • Gilead's Q1 2025 Financial report
    Gilead's Q1 2025 Financial report Financial statements Gilead's Q1 2025 report shows stable revenue, strong HIV and hepatitis sales growth, major R&D progress, and reaffirmed full-year guidance, driven by products like Biktarvy, Trodelvy, and lenacapavir.
  • Global Biopharma Layoffs April 2025
    Global Biopharma Layoffs April 2025 Layoffs Stay updated on recent global biopharma layoffs in April 2025. Learn about job cuts, restructuring plans, and the latest industry developments across leading biotech and pharma companies.
  • 2024 Global CAR-T Sales Performance
    2024 Global CAR-T Sales Performance CAR-T Discover the sales performance of CAR-T therapies in 2024, including Kymriah, Yescarta, Breyanzi, and more. Explore trends, growth, and challenges in the CAR-T cell therapy market across the US and beyond.
  • Biotech Giants Performance Comparison 2024
    Biotech Giants Performance Comparison 2024 Market Trend Compare the 2024 financial performance of top biotech giants, including Vertex, Amgen, Gilead, Regeneron, and Biogen. Explore revenue, net profit, R&D investment, and market trends shaping the biotech industry.
<Pre12Next >
南康市| 柳州市| 南陵县| 溧阳市| 山西省| 昌宁县| 綦江县| 方山县| 宁南县| 绥芬河市| 台北县| 辉县市| 托克逊县| 崇阳县| 兴城市| 冷水江市| 曲沃县| 兖州市| 青河县| 德惠市| 伊川县| 犍为县| 黄大仙区| 兰西县| 永城市| 镇雄县| 台东县| 调兵山市| 蒙山县| 武胜县| 商南县| SHOW| 原平市| 唐山市| 达拉特旗| 苍山县| 西华县| 卢氏县| 隆回县| 建始县| 恩平市|